Header Logo

Connection

Fatima Laher to HIV Infections

Back to Details
This is a "connection" page, showing publications Fatima Laher has written about HIV Infections.
Fatima Laher
Connection Strength
3,583
HIV Infections
  1. Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. Vaccine. 2024 Aug 13; 42(20):125991.
    View in: PubMed
    Score: 0,262
  2. Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline. BMC Med Res Methodol. 2023 06 24; 23(1):147.
    View in: PubMed
    Score: 0,246
  3. Use of Varied Screening Risk Criteria and HIV Incidence in Phase 1 and 2 HIV Vaccine Trials in South Africa. AIDS Behav. 2023 Apr; 27(4):1314-1320.
    View in: PubMed
    Score: 0,235
  4. HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021. AIDS Res Hum Retroviruses. 2022 05; 38(5):350-358.
    View in: PubMed
    Score: 0,220
  5. Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial. PLoS One. 2021; 16(1):e0241708.
    View in: PubMed
    Score: 0,208
  6. Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important. BMC Public Health. 2020 Nov 07; 20(1):1669.
    View in: PubMed
    Score: 0,205
  7. Review of preventative HIV vaccine clinical trials in South Africa. Arch Virol. 2020 Nov; 165(11):2439-2452.
    View in: PubMed
    Score: 0,202
  8. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
    View in: PubMed
    Score: 0,195
  9. HIV research in South Africa: Advancing life. S Afr Med J. 2019 Dec 05; 109(11b):36-40.
    View in: PubMed
    Score: 0,192
  10. Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. PLoS One. 2014; 9(11):e112303.
    View in: PubMed
    Score: 0,135
  11. Conversations with mothers: exploring reasons for prevention of mother-to-child transmission (PMTCT) failures in the era of programmatic scale-up in Soweto, South Africa. AIDS Behav. 2012 Jan; 16(1):91-8.
    View in: PubMed
    Score: 0,111
  12. Role of menstruation in contraceptive choice among HIV-infected women in Soweto, South Africa. Contraception. 2010 Jun; 81(6):547-51.
    View in: PubMed
    Score: 0,097
  13. A qualitative assessment of decisions affecting contraceptive utilization and fertility intentions among HIV-positive women in Soweto, South Africa. AIDS Behav. 2009 Jun; 13 Suppl 1:47-54.
    View in: PubMed
    Score: 0,092
  14. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
    View in: PubMed
    Score: 0,067
  15. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar; 21(3):e1004360.
    View in: PubMed
    Score: 0,065
  16. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023 Jul; 93:104590.
    View in: PubMed
    Score: 0,061
  17. Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa. AIDS Behav. 2023 Sep; 27(9):3027-3037.
    View in: PubMed
    Score: 0,060
  18. A qualitative study of stakeholder and researcher perspectives of community engagement practices for HIV vaccine clinical trials in South Africa. J Community Psychol. 2023 04; 51(3):998-1015.
    View in: PubMed
    Score: 0,059
  19. Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. J Infect Dis. 2022 08 24; 226(2):246-257.
    View in: PubMed
    Score: 0,058
  20. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021 03 25; 384(12):1089-1100.
    View in: PubMed
    Score: 0,053
  21. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 03 18; 384(11):1003-1014.
    View in: PubMed
    Score: 0,053
  22. Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathog. 2021 03; 17(3):e1009363.
    View in: PubMed
    Score: 0,052
  23. Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Sci Rep. 2020 08 03; 10(1):13031.
    View in: PubMed
    Score: 0,050
  24. A mixed methods investigation of implementation barriers and facilitators to a daily mobile phone sexual risk assessment for young women in Soweto, South Africa. PLoS One. 2020; 15(4):e0231086.
    View in: PubMed
    Score: 0,049
  25. Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. Front Immunol. 2019; 10:2741.
    View in: PubMed
    Score: 0,048
  26. Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915). J Acquir Immune Defic Syndr. 2019 06 01; 81(2):e39-e48.
    View in: PubMed
    Score: 0,046
  27. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
    View in: PubMed
    Score: 0,043
  28. Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol. 2016 04; 17:104-109.
    View in: PubMed
    Score: 0,037
  29. Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? PLoS Biol. 2016 Mar; 14(3):e1002372.
    View in: PubMed
    Score: 0,037
  30. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 01; 164(5):313-22.
    View in: PubMed
    Score: 0,037
  31. Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS One. 2015; 10(9):e0137666.
    View in: PubMed
    Score: 0,036
  32. Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One. 2014; 9(8):e103446.
    View in: PubMed
    Score: 0,033
  33. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014 May; 14(5):388-96.
    View in: PubMed
    Score: 0,032
  34. The effect of a maturing antiretroviral program on early mortality for patients with advanced immune-suppression in Soweto, South Africa. PLoS One. 2013; 8(11):e81538.
    View in: PubMed
    Score: 0,032
  35. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011 Mar 09; 6(3):e17518.
    View in: PubMed
    Score: 0,026
  36. Influence of culture on contraceptive utilization among HIV-positive women in Brazil, Kenya, and South Africa. AIDS Behav. 2011 Feb; 15(2):454-68.
    View in: PubMed
    Score: 0,026
  37. Contraceptive use and method preference among women in Soweto, South Africa: the influence of expanding access to HIV care and treatment services. PLoS One. 2010 Nov 05; 5(11):e13868.
    View in: PubMed
    Score: 0,026
  38. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
    View in: PubMed
    Score: 0,025
  39. Responding to her question: a review of the influence of pregnancy on HIV disease progression in the context of expanded access to HAART in sub-Saharan Africa. AIDS Behav. 2009 Jun; 13 Suppl 1:66-71.
    View in: PubMed
    Score: 0,023
  40. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
    View in: PubMed
    Score: 0,012
  41. A high burden of asymptomatic genital tract infections undermines the syndromic management approach among adolescents and young adults in South Africa: implications for HIV prevention efforts. BMC Infect Dis. 2018 Oct 03; 18(1):499.
    View in: PubMed
    Score: 0,011
  42. Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa. AIDS Behav. 2018 Jul; 22(7):2312-2321.
    View in: PubMed
    Score: 0,011
  43. Health-seeking behaviours by gender among adolescents in Soweto, South Africa. Glob Health Action. 2015; 8:25670.
    View in: PubMed
    Score: 0,009
  44. Human papillomavirus genotype distribution among human immunodeficiency virus (HIV)-infected and non-HIV-infected women in Soweto, South Africa. J Clin Microbiol. 2008 Dec; 46(12):4109-10.
    View in: PubMed
    Score: 0,006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.